| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nurix Therapeutics, Inc. (NRIX) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 15 sells. NRIX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 117.0K | $1.92M | -3,214 | |
| CFO | 54.0K | $888.9K | -2,388 | |
| Dir | 50.0K | $822.5K | - | |
| Other | 26.5K | $435.2K | -8,608 | |
| Dir | 25.0K | $411.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2025 | Van Houte Hans62 | Chief Financial Officer | Sale+OE | 2,438 | $11.50 | $28,041.14 | -5.8% | +3.1% | - | |
| Mar 3, 2025 | Van Houte Hans62 | Chief Financial Officer | Sell | 5,825 | $14.49 | $84,387.72 | -7.9% | -14.4% | +11.5% | |
| Jan 31, 2025 | Ring Christine78 | Chief Legal Officer | Sale+OE | 5,760 | $19.95 | $114,933.87 | -8.1% | -43.4% | -16.2% | |
| Jan 30, 2025 | Ring Christine78 | Chief Legal Officer | Sale+OE | 3,220 | $19.85 | $63,928.87 | -4.7% | -42.4% | -17.5% | |
| Jan 30, 2025 | Hansen Gwenn74 | Chief Scientific Officer | Sale+OE | 3,690 | $19.85 | $73,259.85 | -3.2% | -42.4% | -17.5% | |
| Jan 30, 2025 | Van Houte Hans62 | Chief Financial Officer | Sale+OE | 2,811 | $19.85 | $55,808.69 | -3.4% | -42.4% | -17.5% | |
| Jan 2, 2025 | Ring Christine78 | Chief Legal Officer | Sale+OE | 5,760 | $19.50 | $112,294.66 | -17.0% | -41.7% | -7.4% | |
| Dec 2, 2024 | Ring Christine78 | Chief Legal Officer | Sale+OE | 5,760 | $21.73 | $125,155.01 | -17.0% | -34.0% | -23.9% | |
| Nov 4, 2024 | Ring Christine78 | Chief Legal Officer | Sale+OE | 3,290 | $25.00 | $82,250.00 | -10.5% | -24.3% | -51.0% | |
| Nov 1, 2024 | Van Houte Hans62 | Chief Financial Officer | Sell | 3,546 | $24.28 | $86,083.41 | -9.5% | -18.2% | -47.1% |